Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients

Psychiatry Research

Volumn 153, Issue 2, 2007, Pages 103-109

  Arranz, Belén ^a   Rosel, Pilar ^b   San, Luis ^a   Ramírez, Nicolás ^a   Dueñas, Rosa María ^c   Salavert, Josep ^a   Centeno, Meritxell ^c   Moral, Enrique del ^a  

^a HOSPITAL SAN RAFAEL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Benito Menni   (Spain)

Author keywords

5 HT2A receptor; First episode; Inositol trisphosphate; Olanzapine; Platelet; Schizophrenia; Second messenger

Indexed keywords

INOSITOL 1,4,5 TRISPHOSPHATE; KETANSERIN; MIANSERIN; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; BIOLOGICAL TRAIT; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEGATIVE SYNDROME; PARANOID SCHIZOPHRENIA; PATIENT SELECTION; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR DENSITY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; THROMBOCYTE MEMBRANE; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING SITES; FEMALE; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; MALE; PREDICTIVE VALUE OF TESTS; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; TIME FACTORS;

EID: 35148828980     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.12.015     Document Type: Article

References (29)

1. Alfredsson G., and Wiesel F. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 101 (1990) 324-331
2. Amin F., Davidson M., Kahn R.S., Schmeidler J., Stern R., and Knott P.J. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophrenia Bulletin 21 (1995) 53-66
3. Arora R.C., and Meltzer H.Y. Effect of clozapine treatment on serotonin-2 receptor binding in the blood platelets of schizophrenic patients. Neuropsychopharmacology 10 (1994) 109-114
4. Arranz M.J., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P., and Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346 (1995) 281-282
5. Arranz B., Rosel P., Sarró S., Zaldivar E., Cano R., Navarro M.A., and San L. Platelet serotonergic binding sites in alcohol-dependent patients. Alcohol and Alcoholism 34 (1999) 726-732
6. Arranz B., Rosel P., Sarró S., Ramirez N., Cano R., Sanchez J.M., and San L. Altered platelet serotonin 5-HT2A receptor density and second messenger inositol trisphosphate (IP3) levels in drug-free schizophrenic patients. Psychiatry Research 118 (2003) 165-174
7. Ashizawa T., Saito T., and Takahata N. Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine. Psychopharmacology 125 (1996) 185-194
8. Bowers M.B., Swigar M.E., Jatlow P.I., and Goicoechea N. Plasma catecholamine metabolites and early response to haloperidol. Journal of Clinical Psychiatry 45 (1984) 248-251
9. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., True L.L., Foreman M.M., Lucaites V.L., and Calligaro D.O. Antagonism by olanzapine of dopamine D1, serotonin 2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophrenia Research 37 (1999) 107-122
10. Bymaster F., Perry K.W., Nelson D., Wong D.T., Rasmussen K., Moore N.A., and Calligaro D.O. Olanzapine: a basic science update. British Journal of Psychiatry 37 (1999) 36-40
11. Bymaster F.P., Rasmussen K., Calligaro D.O., Nelson D.L., DeLapp N.W., Wong D.T., and Moore N.A. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry 58 suppl 10 (1997) 28-36
12. Coccaro E.F., and Siever L.J. The neuropsychopharmacology of personality disorders. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 1567-1580 1995
13. Cook E.J., Fletcher K., Wainwright M., Marks N., Yan S., and Leventhal B. Primary structure of the human platelet serotonin 5-HT2A receptor: identity with the frontal cortex serotonin 5-HT2A receptor. Journal of Neurochemistry 63 (1994) 465-469
14. Cryan J.F., and Leonard B.E. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human Psychopharmacology Clinical and Experimental 15 (2000) 113-135
15. Davila R., Manero E., Zumarraga M., Andia I., Schweitzer J., and Friedhoff A. Plasma homovanillic acid as a predictor of response to neuroleptics. Archives of General Psychiatry 45 (1988) 564-567
16. Elliot J.M., and Kent A. Comparison of [125I]lysergic-acid diethylamide binding in human frontal cortex and platelet tissue. Journal of Neurochemistry 53 (1989) 191-196
17. Hurlemann R., Boy C., Meyer P.T., Scherk H., Wagner M., Herzog H., Coenen H.H., Vogeley K., Falkai P., Zilles K., Maier W., and Bauer A. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anatomical Embryology 210 (2005) 519-523
18. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-276
19. Lindenmayer J.P., Czobor P., Volavka J., Lieberman J.A., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., and Chakos M. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 65 4 (2004) 551-556
20. Markwell M.A., Haas S.M., Bieber L.L., and Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Analytical Biochemistry 87 (1978) 203-225
21. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. Journal of Pharmacological and Experimental Therapeutics 251 (1989) 238-246
22. Memo M., Kleinman J.E., and Hanbauer I. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus in schizophrenics. Science 221 (1983) 1304-1307
23. Nagaoka S., Iwamoto N., and Arai H. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biological Psychiatry 41 (1997) 857-864
24. Nishino N., Kitamura N., Hashimoto T., Kajimoto Y., Shirai Y., Murakami N., Nakai T., Komure O., Shirawa O., Nita T., and Nakai H. Increase in [3H]cAMP binding sites and decrease in Gi-alpha and Go-alpha immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Research 615 (1993) 41-49
25. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., and San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naïve psychotic patients. American Journal of Psychiatry 163 (2006) 1826-1829
26. Rosel P., Arranz B., San L., Urretavizcaya M., Marcusson J., and Navarro M.A. 5-HT2A receptors and their second messenger IP3 are only correlated in human brain and not in platelets. Neuroscience Research Communications 25 3 (1999) 129-138
27. Rosel P., Arranz B., Urretavizcaya M., Oros M., San L., and Navarro M.A. Altered 5-HT2A and 5-HT4 postsynaptic receptors and their intracellular signalling systems IP3 and cAMP in brains from depressed violent suicide victims. Neuropsychobiology 49 (2004) 189-195
28. Strunecka A., and Ripova D. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us?. Prostaglandins, Leukotrienes and Essential Fatty Acids 61 (1999) 1-5
29. Tollefson G.D., Sanger T.M., Beasley C.M., and Tran P.V. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 43 11 (1998) 803-810